| Product Unit Size | Cost | Quantity | Stock |
|---|
Deltarasin inhibits PDEδ at the farnesyl binding pocket, preventing its association with K-Ras. Deltarasin displays anticancer chemotherapeutic activity, inhibiting cell proliferation in cellular and animal models of pancreatic ductal adenocarcinoma.
| Cas No. | 1440898-82-7 |
|---|---|
| Purity | ≥99% |
| Formula | C40H37N5O • xHCl • 3H2O |
| Formula Wt. | 769.21 |
| IUPAC Name | 1-benzyl-2-[4-[(2S)-2-(2-phenylbenzimidazol-1-yl)-2-piperidin-4-ylethoxy]phenyl]benzimidazole;trihydrochloride; trihydrate |
| Solubility | DMSO 100 mg/mL (165.63 mM) Ethanol 100 mg/mL (165.63 mM) Water Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Zimmermann G, Schultz-Fademrecht C, Küchler P, et al. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. J Med Chem. 2014 Jun 26;57(12):5435-48. PMID: 24884780.
Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature. 2013 May 30;497(7451):638-42. PMID: 23698361.